{"id":"NCT02008318","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Galunisertib in Participants With Myelodysplastic Syndromes","officialTitle":"Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-03","primaryCompletion":"2016-03","completion":"2017-09","firstPosted":"2013-12-11","resultsPosted":"2019-03-07","lastUpdate":"2019-09-11"},"enrollment":43,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndromes"],"interventions":[{"type":"DRUG","name":"Galunisertib","otherNames":["LY2157299"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Phase (ph) 2: Galunisertib + BSC","type":"EXPERIMENTAL"},{"label":"Ph 3: Placebo + BSC","type":"PLACEBO_COMPARATOR"},{"label":"Ph 3: Galunisertib + BSC","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the effect of the study drug known as galunisertib in participants with myelodysplastic syndromes (MDS). Participants with different degrees of disease (very low, low, and intermediate risk) will be studied. The study treatment is expected to last about 6 months for each participant.","primaryOutcome":{"measure":"Percentage of Participants With Hematological Improvement (HI)","timeFrame":"Baseline through end of study treatment (24 weeks)","effectByArm":[{"arm":"Galunisertib at 150 mg","deltaMin":31.7,"sd":null},{"arm":"Arm: Galunisertib at 80 mg","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":14,"countries":["Germany","Italy","Spain"]},"refs":{"pmids":["31481511"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":41},"commonTop":["Diarrhoea","Asthenia","Vomiting","Pyrexia","Fatigue"]}}